Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2025; 17(12): 114084
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.114084
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.114084
Drug-induced liver injury in inflammatory bowel disease: Challenges in diagnosis and monitoring
Arshdeep Singh, Arshia Bhardwaj, Ajit Sood, Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India
Harmeet Kaur, Department of Obstetrics and Gynaecology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India
Ashutosh Bawa, Department of Surgery, Government Medical College, Srinagar 190001, Jammu and Kashmīr, India
Vandana Midha, Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India
Author contributions: Singh A was responsible for conceptualization, data curation, methodology and resources; Singh A and Bhardwaj A drafted the original manuscript; Singh A, Bhardwaj A, Kaur H, Bawa A, Midha V, and Sood A contributed to reviewing, editing, and visualization; Sood A provided supervision.
Conflict-of-interest statement: Sood A received honorarium for speaker events from Pfizer India and Takeda India. The remaining authors disclose no conflicts.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Arshdeep Singh, Associate Professor, Department of Gastroenterology, Dayanand Medical College and Hospital, Tagore Nagar Civil Lines, Ludhiana 141001, Punjab, India. drarshdeepsingh@gmail.com
Received: September 15, 2025
Revised: October 1, 2025
Accepted: November 24, 2025
Published online: December 27, 2025
Processing time: 104 Days and 22.8 Hours
Revised: October 1, 2025
Accepted: November 24, 2025
Published online: December 27, 2025
Processing time: 104 Days and 22.8 Hours
Core Tip
Core Tip: Drug-induced liver injury (DILI) in inflammatory bowel disease (IBD) is often underrecognized due to overlapping hepatobiliary disorders and nonspecific presentations. Distinguishing true DILI from IBD-related liver disease requires systematic evaluation, multidisciplinary input, and structured monitoring strategies. This review synthesizes current evidence on the epidemiology, mechanisms, and diagnostic challenges of DILI in IBD, highlighting practical approaches to optimize early detection and safe therapeutic decision-making.